Drug intelligence / Profile preview

4P004v

Development stage: Unknown
Lead developer: 4Moving Biotech
Modality: Peptides, Small Molecules
Administration: Intraarticular

Overview

4P004v is a veterinary-specific GLP-1 analog being co-developed by BioSenic and 4Moving Biotech for use in dogs recovering from cranial cruciate ligament (CCL) surgery. Administered via intra-articular injection, the drug targets the GLP-1 receptor to exploit its analgesic, anti-inflammatory, anti-catabolic, and anabolic benefits. It is designed to modulate joint inflammation and support tissue repair, positioning it as a potential first-in-class disease-modifying therapy in veterinary orthopedics. The program is currently in Phase 1 clinical development to demonstrate proof of concept in post-operative canine patients.

Other names: 4P004 (veterinary version)

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on 4P004v.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 4P004v.

Explore the full profile